secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069783
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q1 2025 net income $112.9M; advances zorevunersen Phase 3 with Biogen
--------------------------------------------------------------------------------

- Net income $112.9M ($1.90 diluted EPS) in Q1 2025 vs net loss $26.4M ($0.57 per share) in Q1 2024.
- Revenue $158.5M, including $152.4M from Biogen license fee and $6.1M from Acadia partnership.
- Cash position $380.3M as of Mar 31, 2025; projected to fund operations beyond mid-2028.
- Phase 3 EMPEROR study of zorevunersen for Dravet syndrome cleared with FDA, EMA, PMDA; enrollment in Q2 2025.
- Biogen collaboration: $165M upfront, potential $385M milestones, tiered royalties; Stoke retains North America rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017025069783/0000950170-25-069783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017025069783/stok-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer